IBio, Capex To Operating Cash Flow vs Price To Sales Ratio Analysis

IBIO Stock

USD 5.54 0.06 1.07%

IBio, Common financial indicator trend analysis is infinitely more than just investigating iBio, Common Stock recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether iBio, Common Stock is a good investment. Please check the relationship between IBio, Common Capex To Operating Cash Flow and its Price To Sales Ratio accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iBio, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

Capex To Operating Cash Flow vs Price To Sales Ratio

Capex To Operating Cash Flow vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of iBio, Common Stock Capex To Operating Cash Flow account and Price To Sales Ratio. At this time, the significance of the direction appears to have no relationship.

The correlation between IBio, Common's Capex To Operating Cash Flow and Price To Sales Ratio is 0.07. Overlapping area represents the amount of variation of Capex To Operating Cash Flow that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of iBio, Common Stock, assuming nothing else is changed. The correlation between historical values of IBio, Common's Capex To Operating Cash Flow and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Operating Cash Flow of iBio, Common Stock are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Capex To Operating Cash Flow i.e., IBio, Common's Capex To Operating Cash Flow and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.07

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Capex To Operating Cash Flow

Price To Sales Ratio

Price to Sales Ratio is figured by comparing iBio, Common Stock stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on IBio, Common sales, a figure that is much harder to manipulate than other iBio, Common Stock multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from IBio, Common's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into iBio, Common Stock current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iBio, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

At this time, IBio, Common's Issuance Of Capital Stock is very stable compared to the past year. As of the 11th of March 2025, Sales General And Administrative To Revenue is likely to grow to 49.03, while Selling General Administrative is likely to drop about 11.2 M.

	2022	2023	2024	2025 (projected)
Gross Profit	50K	225K	258.8K	245.8K
Total Revenue	50K	225K	258.8K	245.8K

Gross Profit Total Revenue

IBio, Common fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Common Stock Total Equity	Inventory	Net Tangible Assets	Retained Earnings Total Equity
Total Assets		0.42	0.44	0.95	0.84	-0.52	-0.36	0.47	0.91	0.87	0.93	0.88	-0.01	0.4	0.08	0.46	0.82	0.84	0.96	-0.22	0.61	0.69	0.49	-0.09	0.95	-0.68
Other Current Liab	0.42		0.77	0.42	0.18	-0.07	-0.73	0.39	0.2	0.33	0.25	0.32	0.34	-0.43	0.79	0.68	0.34	0.21	0.43	0.59	-0.09	0.25	0.71	0.57	0.36	-0.68
Total Current Liabilities	0.44	0.77		0.4	0.41	0.14	-0.52	0.7	0.1	0.54	0.17	0.51	0.08	-0.35	0.56	0.48	0.44	0.45	0.34	0.48	-0.21	0.43	0.52	0.26	0.37	-0.55
Total Stockholder Equity	0.95	0.42	0.4		0.67	-0.7	-0.39	0.48	0.92	0.73	0.95	0.9	0.07	0.3	0.02	0.5	0.63	0.67	0.97	-0.13	0.63	0.54	0.55	-0.03	0.99	-0.66
Property Plant And Equipment Net	0.84	0.18	0.41	0.67		-0.06	-0.21	0.39	0.64	0.98	0.66	0.69	-0.14	0.48	-0.08	0.27	0.93	1.0	0.66	-0.33	0.36	0.88	0.22	-0.23	0.68	-0.55
Net Debt	-0.52	-0.07	0.14	-0.7	-0.06		0.15	-0.12	-0.77	-0.09	-0.77	-0.58	-0.18	-0.18	0.21	-0.29	-0.02	-0.05	-0.71	0.16	-0.67	0.1	-0.4	-0.03	-0.69	0.25
Retained Earnings	-0.36	-0.73	-0.52	-0.39	-0.21	0.15		-0.01	-0.23	-0.33	-0.24	-0.28	-0.8	0.37	-0.44	-0.97	-0.2	-0.25	-0.34	-0.65	0.25	-0.22	-0.9	-0.86	-0.26	0.89
Accounts Payable	0.47	0.39	0.7	0.48	0.39	-0.12	-0.01		0.28	0.46	0.34	0.62	-0.35	-0.16	0.16	0.02	0.39	0.41	0.43	0.02	0.18	0.35	0.11	-0.28	0.49	-0.16
Cash	0.91	0.2	0.1	0.92	0.64	-0.77	-0.23	0.28		0.64	0.99	0.81	0.0	0.5	-0.1	0.36	0.63	0.63	0.96	-0.37	0.79	0.42	0.4	-0.13	0.92	-0.54
Non Current Assets Total	0.87	0.33	0.54	0.73	0.98	-0.09	-0.33	0.46	0.64		0.67	0.74	-0.04	0.35	0.0	0.39	0.9	0.99	0.7	-0.17	0.3	0.9	0.36	-0.12	0.73	-0.64
Cash And Short Term Investments	0.93	0.25	0.17	0.95	0.66	-0.77	-0.24	0.34	0.99	0.67		0.83	-0.01	0.46	-0.08	0.38	0.64	0.65	0.98	-0.34	0.78	0.49	0.42	-0.14	0.96	-0.54
Net Receivables	0.88	0.32	0.51	0.9	0.69	-0.58	-0.28	0.62	0.81	0.74	0.83		-0.05	0.22	-0.08	0.39	0.62	0.7	0.85	-0.13	0.51	0.45	0.46	-0.13	0.9	-0.58
Common Stock Shares Outstanding	-0.01	0.34	0.08	0.07	-0.14	-0.18	-0.8	-0.35	0.0	-0.04	-0.01	-0.05		-0.51	0.06	0.82	-0.27	-0.11	0.0	0.64	-0.39	-0.04	0.77	0.92	-0.07	-0.52
Non Current Liabilities Total	0.4	-0.43	-0.35	0.3	0.48	-0.18	0.37	-0.16	0.5	0.35	0.46	0.22	-0.51		-0.25	-0.32	0.49	0.44	0.38	-0.79	0.69	0.3	-0.33	-0.62	0.38	0.03
Other Current Assets	0.08	0.79	0.56	0.02	-0.08	0.21	-0.44	0.16	-0.1	0.0	-0.08	-0.08	0.06	-0.25		0.33	0.2	-0.07	0.11	0.41	-0.14	-0.04	0.35	0.42	0.0	-0.37
Other Stockholder Equity	0.46	0.68	0.48	0.5	0.27	-0.29	-0.97	0.02	0.36	0.39	0.38	0.39	0.82	-0.32	0.33		0.22	0.31	0.45	0.55	-0.13	0.27	0.95	0.83	0.38	-0.89
Total Liab	0.82	0.34	0.44	0.63	0.93	-0.02	-0.2	0.39	0.63	0.9	0.64	0.62	-0.27	0.49	0.2	0.22		0.92	0.68	-0.32	0.41	0.76	0.17	-0.24	0.66	-0.57
Property Plant And Equipment Gross	0.84	0.21	0.45	0.67	1.0	-0.05	-0.25	0.41	0.63	0.99	0.65	0.7	-0.11	0.44	-0.07	0.31	0.92		0.66	-0.28	0.32	0.89	0.26	-0.2	0.68	-0.58
Total Current Assets	0.96	0.43	0.34	0.97	0.66	-0.71	-0.34	0.43	0.96	0.7	0.98	0.85	0.0	0.38	0.11	0.45	0.68	0.66		-0.23	0.72	0.49	0.51	-0.06	0.97	-0.63
Intangible Assets	-0.22	0.59	0.48	-0.13	-0.33	0.16	-0.65	0.02	-0.37	-0.17	-0.34	-0.13	0.64	-0.79	0.41	0.55	-0.32	-0.28	-0.23		-0.64	-0.18	0.58	0.76	-0.24	-0.33
Common Stock	0.61	-0.09	-0.21	0.63	0.36	-0.67	0.25	0.18	0.79	0.3	0.78	0.51	-0.39	0.69	-0.14	-0.13	0.41	0.32	0.72	-0.64		0.17	0.0	-0.48	0.69	-0.04
Property Plant Equipment	0.69	0.25	0.43	0.54	0.88	0.1	-0.22	0.35	0.42	0.9	0.49	0.45	-0.04	0.3	-0.04	0.27	0.76	0.89	0.49	-0.18	0.17		0.22	-0.15	0.54	-0.44
Common Stock Total Equity	0.49	0.71	0.52	0.55	0.22	-0.4	-0.9	0.11	0.4	0.36	0.42	0.46	0.77	-0.33	0.35	0.95	0.17	0.26	0.51	0.58	0.0	0.22		0.78	0.44	-0.8
Inventory	-0.09	0.57	0.26	-0.03	-0.23	-0.03	-0.86	-0.28	-0.13	-0.12	-0.14	-0.13	0.92	-0.62	0.42	0.83	-0.24	-0.2	-0.06	0.76	-0.48	-0.15	0.78		-0.16	-0.56
Net Tangible Assets	0.95	0.36	0.37	0.99	0.68	-0.69	-0.26	0.49	0.92	0.73	0.96	0.9	-0.07	0.38	0.0	0.38	0.66	0.68	0.97	-0.24	0.69	0.54	0.44	-0.16		-0.57
Retained Earnings Total Equity	-0.68	-0.68	-0.55	-0.66	-0.55	0.25	0.89	-0.16	-0.54	-0.64	-0.54	-0.58	-0.52	0.03	-0.37	-0.89	-0.57	-0.58	-0.63	-0.33	-0.04	-0.44	-0.8	-0.56	-0.57

Click cells to compare fundamentals

IBio, Common Account Relationship Matchups

IBio, Common fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	147.0M	99.4M	41.2M	28.7M	33.0M	38.8M
Other Current Liab	3.3M	3.5M	5.9M	2.3M	2.7M	1.9M
Total Current Liabilities	6.6M	30.4M	21.6M	3.8M	4.4M	6.2M
Total Stockholder Equity	108.6M	63.5M	15.4M	21.3M	24.5M	20.0M
Property Plant And Equipment Net	34.7M	41.8M	7.6M	6.4M	7.3M	13.6M
Net Debt	(44.7M)	5.1M	12.8M	(9.8M)	(8.8M)	(8.3M)
Retained Earnings	(173.6M)	(223.9M)	(288.9M)	(313.8M)	(282.5M)	(268.3M)
Accounts Payable	2.3M	4.3M	1.8M	358K	411.7K	391.1K
Cash	77.4M	22.7M	4.3M	14.2M	16.3M	15.5M
Non Current Assets Total	42.4M	54.3M	14.9M	13.1M	15.0M	17.9M
Cash And Short Term Investments	97.0M	33.5M	4.3M	14.2M	16.3M	17.3M
Net Receivables	5.5M	6.1M	204K	713K	820.0K	1.3M
Common Stock Shares Outstanding	782.5K	872.1K	1.2M	3.8M	4.4M	4.6M
Liabilities And Stockholders Equity	147.0M	99.4M	41.2M	28.7M	33.0M	38.8M
Non Current Liabilities Total	31.8M	5.5M	4.2M	3.6M	3.2M	3.1M
Other Current Assets	2.1M	1.5M	21.8M	749K	861.4K	818.3K
Other Stockholder Equity	282.1M	287.6M	304.3M	335.2M	385.4M	404.7M
Total Liab	38.4M	35.9M	25.8M	7.4M	8.5M	8.1M
Property Plant And Equipment Gross	34.7M	45.3M	8.2M	7.9M	9.0M	13.9M
Total Current Assets	104.6M	45.1M	26.3M	15.7M	18.0M	20.9M
Intangible Assets	952K	4.9M	5.4M	5.4M	6.2M	3.2M
Common Stock	20K	140K	217K	9K	10.4K	9.8K
Property Plant Equipment	3.7M	34.7M	41.8M	7.6M	8.7M	13.8M
Inventory	798K	27K	3.9M	21.1M	24.3M	25.5M
Net Tangible Assets	56.6M	107.6M	58.6M	10.0M	11.5M	10.9M
Short Term Debt	1.3M	22.3M	13.6M	953K	1.1M	1.0M
Accumulated Other Comprehensive Income	(31K)	(33K)	(63K)	(213K)	(191.7K)	(182.1K)
Short Long Term Debt Total	32.7M	27.8M	17.1M	4.5M	4.0M	3.8M
Current Deferred Revenue	423K	100K	4.2M	200K	230K	218.5K
Non Currrent Assets Other	6.7M	7.7M	2.0M	1.3M	1.5M	2.2M
Capital Lease Obligations	32.1M	5.6M	4.1M	3.5M	3.1M	3.0M
Short Long Term Debt	600K	22.2M	12.9M	218K	196.2K	186.4K

Pair Trading with IBio, Common

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if IBio, Common position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in IBio, Common will appreciate offsetting losses from the drop in the long position's value.

Moving against IBio, Stock

0.8	MNOV	MediciNova	Pair Corr
0.77	NKTX	Nkarta Inc	Pair Corr
0.76	IMMX	Immix Biopharma	Pair Corr
0.75	PALI	Palisade Bio	Pair Corr
0.73	MLTX	MoonLake Immunotherapeuti	Pair Corr

The ability to find closely correlated positions to IBio, Common could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace IBio, Common when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back IBio, Common - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling iBio, Common Stock to buy it.

The correlation of IBio, Common is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as IBio, Common moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if iBio, Common Stock moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for IBio, Common can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether iBio, Common Stock offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IBio, Common's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ibio, Common Stock Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ibio, Common Stock Stock:

How To Invest In IBio,

Details

Is IBio, Stock a good investment?

Details

What is IBio, Common's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iBio, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IBio, Common. If investors know IBio, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IBio, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.03)

Revenue Per Share

0.059

Quarterly Revenue Growth

(0.88)

Return On Assets

(0.30)

Return On Equity

(0.84)

The market value of iBio, Common Stock is measured differently than its book value, which is the value of IBio, that is recorded on the company's balance sheet. Investors also form their own opinion of IBio, Common's value that differs from its market value or its book value, called intrinsic value, which is IBio, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IBio, Common's market value can be influenced by many factors that don't directly affect IBio, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between IBio, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if IBio, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IBio, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

IBio, Capex To Operating Cash Flow vs Price To Sales Ratio Analysis

Capex To Operating Cash Flow vs Price To Sales Ratio

Capex To Operating Cash Flow vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Capex To Operating Cash Flow

Price To Sales Ratio

IBio, Common fundamental ratios Correlations

IBio, Common Account Relationship Matchups

High Positive Relationship

High Negative Relationship

IBio, Common fundamental ratios Accounts

Pair Trading with IBio, Common

Moving against IBio, Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Cash
Property Plant And Equipment Gross	+ 0.99	Non Current Assets Total
Non Current Assets Total	+ 0.98	Property Plant And Equipment Net
Total Current Assets	+ 0.98	Cash And Short Term Investments

Other Stockholder Equity	- 0.97	Retained Earnings
Common Stock Total Equity	- 0.9	Retained Earnings
Retained Earnings Total Equity	- 0.89	Other Stockholder Equity
Inventory	- 0.86	Retained Earnings
Retained Earnings Total Equity	- 0.8	Common Stock Total Equity
Common Stock Shares Outstanding	- 0.8	Retained Earnings